US 11,897,864 B2
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Milan Bruncko, Green Oaks, IL (US); Hong Ding, Gurnee, IL (US); George A. Doherty, Libertyville, IL (US); Steven W. Elmore, Northbrook, IL (US); Lisa A. Hasvold, Grayslake, IL (US); Laura Hexamer, Grayslake, IL (US); Aaron R. Kunzer, Schaumburg, IL (US); Xiaohong Song, Grayslake, IL (US); Andrew J. Souers, Evanston, IL (US); Gerard M. Sullivan, Lake Villa, IL (US); Zhi-Fu Tao, Gurnee, IL (US); Gary T. Wang, Libertyville, IL (US); Le Wang, Vernon Hills, IL (US); Xilu Wang, Grayslake, IL (US); Michael D. Wendt, Vernon Hills, IL (US); Robert Mantei, Franklin, WI (US); and Todd M. Hansen, Grayslake, IL (US)
Assigned to AbbVie Inc., North Chicago, IL (US); Genentech, Inc., South San Francisco, CA (US); and The Walter and Eliza Hall Institute of Medical Research, Parkville (AU)
Filed by AbbVie Inc., North Chicago, IL (US); Genentech, Inc., South San Francisco, CA (US); and The Walter and Eliza Hall Institute of Medical Research, Parkville (AU)
Filed on Oct. 7, 2022, as Appl. No. 17/938,835.
Application 17/938,835 is a continuation of application No. 17/518,249, filed on Nov. 3, 2021, abandoned.
Application 17/518,249 is a continuation of application No. 17/004,841, filed on Aug. 27, 2020, abandoned.
Application 17/004,841 is a continuation of application No. 16/557,819, filed on Aug. 30, 2019, abandoned.
Application 16/557,819 is a continuation of application No. 15/993,521, filed on May 30, 2018, abandoned.
Application 15/993,521 is a continuation of application No. 15/219,208, filed on Jul. 25, 2016, abandoned.
Application 15/219,208 is a continuation of application No. 14/694,965, filed on Apr. 23, 2015, abandoned.
Application 14/694,965 is a continuation of application No. 13/830,926, filed on Mar. 14, 2013, granted, now 9,045,475, issued on Jun. 2, 2015.
Application 13/830,926 is a continuation of application No. 12/787,682, filed on May 26, 2010, granted, now 8,546,399, issued on Oct. 1, 2013.
Claims priority of provisional application 61/181,203, filed on May 26, 2009.
Prior Publication US 2023/0143532 A1, May 11, 2023
Int. Cl. C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 519/00 (2006.01); C07D 471/04 (2006.01); C07D 209/82 (2006.01); C07D 403/12 (2006.01); A61K 31/496 (2006.01)
CPC C07D 401/12 (2013.01) [A61K 31/496 (2013.01); C07D 209/82 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01); Y02A 50/30 (2018.01)] 27 Claims
 
1. A compound having Formula (II)

OG Complex Work Unit Chemistry
or a therapeutically acceptable salt thereof, wherein:
n is 0;
A1 is C(A2);
A2, D1, and E1 are H;
B1 is NHR1;
Y1 is NO2;
R1 is methyl, which is substituted with one heterocycloalkyl;
Z2 is piperazinyl;
L1 is methylene;
Z3 is cycloalkenyl substituted with R57A and R57;
R57A is spiroalkyl; and
R57 is phenyl substituted with one Cl.